Skip to main content
. 2021 Oct 19;11(10):1541. doi: 10.3390/biom11101541

Table 9.

Drugs in Clinical Trials and Residues Targeted.

Name of Drug Amyloid β Residues Targeted
aducanumab 3–7 (6, 25)
gantenerumab 3–11 and 18–27 (6, 25)
crenezumab 13–24 (6, 25)
solanezumab 16–26 (6, 25)
lecanemab 1–16 (6, 25)
donanemab 3–7 (25)

These drugs are in a stage of clinical trials and the residues they target are also shown with them. This was used for the analysis of the residues as it indicates what other researchers predicted significant residues are.